Chemomab Therapeutics
Pharmaceutical ManufacturingView the employees at
Chemomab Therapeutics-
Matthew Frankel MD CMO and VP Clinical Development
-
Princeton, New Jersey, United States
-
Rising Star
Omer Levy ---
Israel
-
Rising Star
Jack Lawler Vice President, Global Clinical Development Operations-
Greater Philadelphia
-
Top 5%
Yafit Sadot Clinical Trials Manager-
Center District, Israel
-
Rising Star
Barbara Lindheim Consulting VP of Strategic Communications at Chemomab Therapeutics-
New York, New York, United States
-
Top 5%
Overview
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
-